Evidence map›Paper›PMID 41911333›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

β-Triketone-Based Ionizable Cationic Lipids Synthesized via Click Chemistry for siRNA Delivery.

Huatian Li, Haocheng Tang, Yiqing Mu, Shangyu Chen, Paul Edward Floreancig, Junmei Wang, Yixian Huang, Song Li

Abstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Huatian LiCenter for Pharmacogenetics, Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Haocheng TangComputational Chemical Genomics Screening Center, Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Yiqing MuCenter for Pharmacogenetics, Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Shangyu ChenCenter for Pharmacogenetics, Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Paul Edward FloreancigDepartment of Chemistry, Dietrich School of Arts and Sciences, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Junmei WangComputational Chemical Genomics Screening Center, Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Yixian HuangCenter for Pharmacogenetics, Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Song LiCenter for Pharmacogenetics, Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.ORCID https://orcid.org/0000-0003-1658-949X

Funding

Immunostimulatory Nanocarrier for Breast Cancer ImmunochemotherapyR01CA219399 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI LI, SONG · 2017 to 2021
$2.3M
Nanotherapeutics for Synergistic Targeting of Myc in Prostate CancerR01CA223788 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI LI, SONG · 2018 to 2022
$1.8M
New Generation of General AMBER Force Field for Biomedical ResearchR01GM147673 · NIGMS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI WANG, JUNMEI, YANG, WEI · 2022 to 2025
$1.5M
AI-Powered Biased Ligand DesignR01GM149705 · NIGMS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Junmei Wang · 2023 to 2026
$1.3M
Targeting iRhom to Improve Colon Cancer ImmunochemotherapyR01CA295774 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Song Li · 2025 to 2026
$1.1M
NIH HHS R01CA219399NIH HHS R01CA223788NIH HHS R01CA295774NIH HHS R01GM147673NIH HHS R01GM149705NIH HHS RO1CA270623NIH HHS RO1CA278608
6 · The paper itself

Abstract

Lipid nanoparticles (LNPs) have demonstrated their effectiveness as carriers for the delivery of RNA therapeutics. As the core components of the LNP system, ionizable cationic lipids (ICLs) are still the major focus of research in this field. In this study, we reported a class of novel β-triketone-based ICLs synthesized via click chemistry. We demonstrated that the reaction could be completed instantaneously, and a library of ICLs was generated in a short time. In vitro and in vivo screening identified a lipid that was comparable to FDA approved Dlin-MC3-DMA lipid in siRNA LNPs-mediated gene silencing. In addition, we adopted a computational approach to characterizing the click chemistry in lipid synthesis, as well as the binding between siRNA and ICLs. Our work offers a novel approach to synthesizing ICLs of new structural features, which may not only improve our understanding of the structure-activity relationship (SAR) of ICLs but also lead to the development of improved LNPs for more effective delivery of nucleic acid therapeutics.

Indexed as

Click ChemistryKetonesLipidsNanoparticlesRNA, Small InterferingAnimalsCationsGene SilencingHumansCationsKetonesLipidsRNA, Small Interferingclick chemistryionizable lipidslipid nanoparticlesSiRNAβ‐triketone

Identifiers

PMID41911333
PMCPMC13159103

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.